Please check your internet connection and try again.
# Flupentixol and Melitracen
## Overview
Flupentixol is a typical (first-generation) antipsychotic of the thioxanthene class. Melitracen is a tricyclic antidepressant (TCA). This combination is available in some countries, often marketed as Deanxit, and is used for treating anxiety and depression.
## Primary Indications
Treatment of anxiety and depression, particularly when accompanied by apathy or lack of motivation.
## Adult Dosing
* **Typical Starting Dose:** 1 tablet twice daily (morning and evening).
* **Typical Maintenance Dose:** 1 tablet twice daily, or 1 tablet three times daily if needed.
* **Maximum Dose:** Not clearly established for the combination product. Individual components' maximums may be relevant but a specific combined maximum is not universally defined. Dosing should be individualized.
## Pediatric Dosing
* There is **limited to no established pediatric dosing** for flupentixol and melitracen combination products. Use in pediatric populations is generally not recommended due to safety and efficacy concerns.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. Dose reduction may be necessary based on patient response and tolerance.
* **Renal Impairment:** No specific dose adjustments are routinely recommended, but caution is advised, especially in severe impairment.
* **Elderly:** May be more sensitive to side effects; start with a lower dose and titrate cautiously.
## Contraindications
* Hypersensitivity to flupentixol, melitracen, or other thioxanthenes/TCAs.
* Acute intoxication with alcohol or central nervous system depressants.
* Circulatory collapse.
* Severe hepatic or renal impairment.
* Untreated narrow-angle glaucoma.
* Prostatic hyperplasia with urinary retention.
* Recent myocardial infarction.
* Certain cardiac arrhythmias (e.g., significant conduction defects).
## Adverse Effects
* **Common:** Sedation, dry mouth, blurred vision, constipation, urinary retention, dizziness, headache, tachycardia.
* **Less Common/Serious:** Extrapyramidal symptoms (EPS) such as akathisia, dystonia, parkinsonism (more common with flupentixol component), tardive dyskinesia (risk increases with duration of use), orthostatic hypotension, anticholinergic toxicity, cardiac effects (QT prolongation, arrhythmias), confusion, sexual dysfunction. Withdrawal symptoms can occur.
## Key Drug Interactions
* **CNS Depressants (e.g., alcohol, benzodiazepines, opioids):** Additive sedative effects.
* **MAO Inhibitors:** Increased risk of hypertensive crisis or serotonin syndrome. Discontinue MAOIs 14 days before starting flupentixol/melitracen and vice versa.
* **Anticholinergic Agents:** Increased anticholinergic effects.
* **Sympathomimetic Agents:** Potential for exaggerated pressor response.
* **QTc Prolonging Agents:** Increased risk of QT interval prolongation and arrhythmias.
* **CYP450 Inhibitors/Inducers:** May affect flupentixol metabolism (primarily CYP2D6).
## Monitoring
* **Initial:** Monitor for therapeutic response and adverse effects (sedation, anticholinergic effects, orthostatic hypotension, EPS).
* **Ongoing:** Periodic assessment of mental status, mood, anxiety symptoms, and side effects. Monitor vital signs, particularly blood pressure and heart rate. Consider ECG monitoring if cardiac risk factors are present or if QTc prolongation is suspected.
## Clinical Pearls
* The combination aims to address both anxiety and depressive symptoms, including apathy.
* Sedation is common, so administration at bedtime or in divided doses may be preferred.
* Due to anticholinergic effects, caution is advised in the elderly and those with glaucoma or urinary retention.
* Risk of EPS and tardive dyskinesia with the flupentixol component necessitates careful monitoring, especially with long-term use.
* Abrupt discontinuation can lead to withdrawal symptoms. Tapering is recommended.
***
***Disclaimer:** This information is intended for clinical pharmacists and is not a substitute for professional medical advice. Always consult the most current prescribing information and relevant guidelines for definitive patient care decisions. Local protocols may vary.*
